Abstract
Dendritic cells (DCs) have antigen-specific bioactivity against tumor-associated antigens. The acquisition of tumor immunity with DC vaccination could be determined using both tetramer analysis and interferon γ-producing clones in enzyme-linked immunosorbent spot assays. A combination of DC vaccination with low-dose metronomic therapy and chemoradiotherapy would contribute to an enhanced acquired immunity for cancer therapy. The efficacy of DC vaccination may provide a survival benefit in some patients with cancer by achieving a prolonged quality-adjusted life year.
Highlights
Dendritic cells (DCs) have antigen-specific bioactivity against tumor-associated antigens
Factors affecting the induction of tumor antigen-specific cytotoxic T cells (CTLs) with DC vaccination remain to be completely elucidated
DC vaccines primed with Wilms’ tumor 1 (WT1)-class I/II peptides were safe during chemotherapy for pancreatic cancer [3]
Summary
Dendritic cells (DCs) have antigen-specific bioactivity against tumor-associated antigens. Dendritic cells (DCs) may have antigen-specific bioactivity against tumor-associated antigens. Factors affecting the induction of tumor antigen-specific cytotoxic T cells (CTLs) with DC vaccination remain to be completely elucidated.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
